Tag: M.W:500-600

1334177-86-4, 1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid is a pyrrolines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Piperidine (0.2 mL) was added to a solution of 90 (77 mg, 63.4 pmol) in DMF (1 mL). The reaction mixture was allowed to stir for 20 minutes. The reaction mixture was carefully diluted with DCM (50 mL) and washed with water (50 mL). The organic layers was washed with brine (100 mL), dried over Mg504, filtered and evaporated under reduced pressure to provide the unprotected valine intermediate. The crude residue was immediately redissolved in chloroform (5 mL). Mal(Peg)8-acid (56 mg, 95 pmol) and EDCI (18 mg, 95 pmol) were added, followed by methanol (0.1 mL). The reaction was allowed to stir for 3 hours at room temperature at which point completion was observed by TLC and LC/MS (1.19 mm (ES+) m/z(relative intensity) 784.25 (([M+ 2H]2)/2, 100)). The reaction mixture was diluted with chloroform (50 mL), washed with water (100 mL), dried (MgSO4), filtered and evaporated in vacuo, followed by high vacuum drying, to provide the crude product. Purification by flash chromatography (gradient elution: HPLC grade 96:4 v/v CHCI3/MeOH to 90:10 v/v CHCI3/MeOH) gave 91 as a yellow solid (43 mg, 43%). 1H NMR (400 MHz, ODd3) 6 8.73 (s, 1 H), 7.88 (dd, J = 7.6, 3.9 Hz, 2H), 7.75 (d, J = 8.6 Hz, 2H), 7.52 (d, J = 2.0 Hz, 2H), 7.44 (s, 1 H), 7.40 – 7.28 (m, 4H), 6.91 (d, J = 8.8 Hz, 2H), 6.81 (s, 2H), 6.69 (s, 2H),6.48 (s, 1 H), 4.72 – 4.63 (m, 1 H), 4.46 – 4.34 (m, 2H), 4.25 – 4.03 (m, 6H), 3.95 (s, 4H), 3.84 (dd, J 17.2, 10.1 Hz, 4H), 3.72-3.46 (m, 30H), 3.44-3.32 (m, 4H), 3.30-3.20 (m, 4H), 2.75 – 2.63 (m, 1 H), 2.59 (s, 4H), 2.55 – 2.43 (m, 3H), 2.37 (s, 3H), 2.29 (dd, J = 12.7, 6.7 Hz, 1 H), 2.03 – 1.89 (m, 4H), 1.72 (d, J = 22.7 Hz, 8H), 1.46 (d, J = 7.2 Hz, 3H), 1.01 (dd, J = 11 .5, 6.9 Hz, 6H). MS (ES) m/z (relative intensity) 784.25 (([M + 2H] 2+)/2, 100).

1334177-86-4, The synthetic route of 1334177-86-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; VAN BERKEL, Patricius Hendrikus Cornelis; HOWARD, Philip Wilson; (290 pag.)WO2016/166299; (2016); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1334177-86-4,1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid,as a common compound, the synthetic route is as follows.

A solution of compound 39 (0.136 g, 0.1 mmol, 1 .0 eq.), Mal-dPEG8-OH (0.066 g, 0.1 1 mmol, 1.1 eq.) and EDCI.HCI (0.022 g, 0.1 1 mmol, 1.1 eq.) in dry DCM (10 mL) and MeOH (1 drop) was stirred at room temperature for 1.45h. The reaction mixture was diluted with CHC and washed with water, brine, dried (MgS04) and evaporated under reduced pressure to give the crude product. Purification by flash column chromatography [CHC /MeOH 1 % to 9%] gave the product as a white solid (0.123 g, 63%). Analytical Data: [a]21D = +1 12.5 (c = 0.4, hplc CHCI3); RT 6.37 min; MS (ES+) m/z (relative intensity) 1936 {[M + 1]+ , 35); 1958 {[M + Na]+ , 15)., 1334177-86-4

The synthetic route of 1334177-86-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; MEDIMMUME LIMITED; HOWARD, Philip Wilson; DUNNY, Elizabeth; MASTERSON, Luke; (151 pag.)WO2017/137553; (2017); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1334177-86-4,1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid,as a common compound, the synthetic route is as follows.

Piperidine (0.2 mL) was added to a solution of 25 (77 mg, 63.4 pmol) in DMF (1 mL). The reaction mixture was allowed to stir for 20 minutes. The reaction mixture was carefullydiluted with DCM (50 mL) and washed with water (50 mL). The organic layers was washed with brine (100 mL), dried over Mg504, filtered and evaporated under reduced pressure to provide the unprotected valine intermediate. The crude residue was immediately redissolved in chloroform (5 mL). Mal(Peg)8-acid (56 mg, 95 pmol) and EDCI (18 mg, 95 pmol) were added, followed by methanol (0.1 mL). The reaction was allowed to stir for 3 hours at room temperature at which point completion was observed by TLC and LC/MS(1.19 mm (ES+) m/z (relative intensity) 784.25 (([M + 2H]2)/2, 100)). The reaction mixture was diluted with chloroform (50 mL), washed with water (100 mL), dried (MgSO4), filtered and evaporated in vacuo, followed by high vacuum drying, to provide the crude product. Purification by flash chromatography (gradient elution: HPLC grade 96:4 v/v CHCI3/MeOH to 90:10 v/v CHCI3/MeOH) gave 26 as a yellow solid (43 mg, 43%). 1H NMR (400 MHz, CDCI3)58.73 (s, IH), 7.88 (dd, J= 7.6, 3.9 Hz, 2H), 7.75 (d, J= 8.6 Hz, 2H), 7.52 (d, J= 2.0 Hz,2H), 7.44 (s, I H), 7.40 – 7.28 (m, 4H), 6.91 (d, J = 8.8 Hz, 2H), 6.81 (s, 2H), 6.69 (s, 2H),6.48 (s, I H), 4.72 – 4.63 (m, I H), 4.46 – 4.34 (m, 2H), 4.25 – 4.03 (m, 6H), 3.95 (s, 4H), 3.84(dd, J= 17.2, 10.1 Hz, 4H), 3.72-3.46 (m, 30H), 3.44-3.32 (m, 4H), 3.30-3.20 (m, 4H),2.75 – 2.63 (m, I H), 2.59 (s, 4H), 2.55 – 2.43 (m, 3H), 2.37 (s, 3H), 2.29 (dd, J = 12.7, 6.7Hz, IH), 2.03-1.89 (m, 4H), 1.72 (d, J= 22.7 Hz, 8H), 1.46 (d, J= 7.2 Hz, 3H), 1.01 (dd, J = 11 .5, 6.9 Hz, 6H). MS (ES) m/z (relative intensity) 784.25 (([M + 2H] 2+)/2 100)., 1334177-86-4

The synthetic route of 1334177-86-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; SPIROGEN SARL; ADC THERAPEUTICS SARL; HOWARD, Philip Wilson; VAN BERKEL, Patricius Hendrikus Cornelis; WO2015/52533; (2015); A1;; ; Patent; SPIROGEN SARL; ADC THERAPEUTICS SARL; HOWARD, Philip Wilson; VAN BERKEL, Patricius Hendrikus Cornelis; WO2015/52534; (2015); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

1334177-86-4, 1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid is a pyrrolines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

EDCI.HCI (117 mg, 0.29 mmol) was added to a stirred solution of MAL-dPEG8-acid (360mg, 0.6079 mmol, Stratech Scientific Limited) and amine 120 (608 mg, 0.5526 mmol) inCH2CI2 (15 mL) at room temperature. The reaction mixture was stirred under an argon atmosphere for 24 hours, at which point analysis by LC/MS showed complete consumption of 120. The reaction mixture was diluted with CH2CI2 and washed successively with sat. NH4CI and sat. NaH 003, dried over Mg504, and concentrated in vacuo to provide thecrude product. Purification by lsoleraTM (4-16% MeOH in CH2CI2) gave amide 121 as a white solid (77 mg, 79% purity (UV integration 223 nm) 8.8% crude yield; 107 mg, 88% purity, 12% crude yield; 224 mg, 86% purity, 25% crude yield)., 1334177-86-4

As the paragraph descriping shows that 1334177-86-4 is playing an increasingly important role.

Reference£º
Patent; MEDIMMUNE LIMITED; HOWARD, Philip Wilson; GREGSON, Stephen John; (207 pag.)WO2018/192944; (2018); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1334177-86-4,1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid,as a common compound, the synthetic route is as follows.,1334177-86-4

Chloroform (1 0.00 ml) and methanol (0.4 ml) were added to crude 17 (307 mg, 0.254 30 mmol) followed by mal-amido-peg8-acid (339 mg, 0.561 mmol, 2.2 eq) and EDCI (1 07 mg, 0.558 mmol, 2.19 eq). The reaction was allowed to proceed at room temperature for 45 min when completion was observed by LCMS. Ammonium chloride in water (30 ml, 6 mass%) was added and the mixture was stirred vigorously. The mixture was decanted in a biotage phase separation cartridge. The DCM layer was evaporated to dryness under vacuum. 35 The volatiles were removed by rotoevaporation and the crude residue was purified by chromatography (50g Ultra, Biotage, gradient 30/70 to 100/0 of 16% MeOH in DCM I DCMin 1 OCV; Elution at more than 10% of MeOH). All fractions were analysed by TLC (1 0% MeOH in DCM). The pure fractions were pooled. The solvent was removed by evaporation to give 18 (200 mg). LCMS analysis showed traces of mal-pegS-acid, and the material was purified further by preparative HPLC, freeze-dried, aliquoted in dichloromethane, and dried 5 under high vacuum to give 18 as a white solid. The purity was 99.45%. (B, 110 mg, 0.0467 mmol, 18.3% Yield). Analytical Data: LC/MS, 15 min method, RT 5.90 min; MS (ES+) m/z (relative intensity) 1179.5 ([M + 2Hf+¡¤, 100); 1H NMR (400 MHz, DMSO-d6) o 9.92 (s, 2H), 8.16 (d, J = 6.9 Hz, 2H), 7.99 (t, J = 5.7 Hz, 2H), 7.86 (d, J = 8.7 Hz, 2H), 7.55 (s, 4H), 7.18 (s, 4H), 7.07 (s, 2H), 7.00 (s, 4H), 6.79 (s, 2H), 6.50 (s, 2H), 5.48 (s, 2H), 5.23- 4.77 (m, 10 4H), 4.39 (t, J = 7.0 Hz, 2H), 4.22 (dd, J = 8.7, 6.6 Hz, 2H), 4.10 (s, 4H), 3.77 (s, 6H), 3.64 – 3.55 (m, 8H), 3.55- 3.42 (m, 56H), 3.37 (t, J = 5.9 Hz, 6H), 3.28 (t, J = 8.3 Hz, 2H), 3.15 (q, J = 5.8 Hz, 4H), 2.49-2.37 (m, 4H), 2.37-2.30 (m, 4H), 2.17 (s, 2H), 2.09- 1.73 (m, 1 OH), 1.30 (d, J = 7.0 Hz, 6H), 0.85 (dd, J = 15.3, 6.7 Hz, 12H). 15

1334177-86-4 1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid 51340955, apyrrolines compound, is more and more widely used in various fields.

Reference£º
Patent; MEDIMMUNE LIMITED; DIMASI, Nazzareno; HOWARD, Philip Wilson; MASTERSON, Luke; TIBERGHIEN, Arnaud Charles; VIJAYAKRISHNAN, Balakumar; WHITE, Jason; (135 pag.)WO2019/34764; (2019); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1334177-86-4,1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid,as a common compound, the synthetic route is as follows.

EDCI hydrochloride (8 mg, 0.042 mmol) was added to a suspension of Maleimide-PEG8-acid(25 mg, 0.042 mmol) in dry CH2CI2 (4 mL) under argon atmosphere. PBD 19 (42 mg, crude)was added straight away and stirring was maintained until the reaction was complete (3hours). The reaction was diluted with CH2CI2 and the organic phase was washed with H20 and brine before being dried over MgSO4, filtered and excess solvent removed by rotary evaporation under reduced pressure by rotary evaporation under reduced pressure. The product was purified by careful silica gel chromatography (slow elution starting with 100%CHCI3 up to 9:1 CHCI3/MeOH) followed by reverse phase HPLC to remove unreacted maleimide-PEG8-acid. The product 20 was isolated in 10% over two steps (6.6 mg). LC/MS 1.16 mm (ES+) m/z (relative intensity) 770.20 ([M + 2H], 40%)., 1334177-86-4

As the paragraph descriping shows that 1334177-86-4 is playing an increasingly important role.

Reference£º
Patent; SPIROGEN SARL; ADC THERAPEUTICS SARL; HOWARD, Philip Wilson; VAN BERKEL, Patricius Hendrikus Cornelis; WO2015/52532; (2015); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1334177-86-4,1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid,as a common compound, the synthetic route is as follows.

(d) 1-(3-(2, 5-dioxo-2 , 5-dihydro- 1H-pyrrol- 1-yl)propanamido)-N-((S)- 1-(((S)- 1-((4-((S)-7- methoxy-8-((5-(((S)- 7-methoxy-2-(4-(4-methylpiperazin- 1-yl)phenyl)-5-oxo-5, 1 la-dihydro- 1H- benzo[e]pyrrolo[1, 2-a][1, 4]diazepin-8-yl) oxy)pentyl) oxy)-5-oxo-5, 1 la-dihydro- 1H- benzo[e]pyrrolo[1, 2-a][1, 4]diazepin-2-yl)phenyl)amino) – 1-oxopropan-2-yl)amino)-3-methyl- 1- oxobutan-2-yl)-3, 6,9, 12,15, 18,21, 24-octaoxaheptacosan-2 7-amide (91)Piperidine (0.2 mL) was added to a solution of 90 (77 mg, 63.4 pmol) in DMF (1 mL). The reaction mixture was allowed to stir for 20 minutes. The reaction mixture was carefully diluted with DCM (50 mL) and washed with water (50 mL). The organic layers was washed with brine (100 mL), dried over Mg504, filtered and evaporated under reduced pressure to provide the unprotected valine intermediate. The crude residue was immediately redissolved in chloroform (5 mL). Mal(Peg)8-acid (56 mg, 95 pmol) and EDCI (18 mg, 95 pmol) were added, followed by methanol (0.1 mL). The reaction was allowed to stir for 3 hours at room temperature at which point completion was observed by TLC and LC/MS (1.19 mm (ES+) m/z(relative intensity) 784.25 (([M+ 2H]2j/2, 100)). The reaction mixture was diluted with chloroform (50 mL), washed with water (100 mL), dried (MgSO4), filtered and evaporated in vacuo, followed by high vacuum drying, to provide the crude product. Purification by flash chromatography (gradient elution: HPLC grade 96:4 v/v CHCI3/MeOH to 90:10 v/v CHCI3/MeOH) gave 91 as a yellow solid (43 mg, 43%). 1H NMR (400 MHz, ODd3) O 8.73 (5, 1H), 7.88 (dd, J= 7.6, 3.9 Hz, 2H), 7.75 (d, J= 8.6 Hz, 2H), 7.52 (d, J= 2.0 Hz, 2H), 7.44 (5, 1H), 7.40-7.28 (m, 4H), 6.91 (d, J= 8.8 Hz, 2H), 6.81 (5, 2H), 6.69 (5, 2H),6.48 (5, 1 H), 4.72 -4.63 (m, 1 H), 4.46 -4.34 (m, 2H), 4.25 – 4.03 (m, 6H), 3.95 (5, 4H), 3.84 (dd, J = 17.2, 10.1 Hz, 4H), 3.72 -3.46 (m, 30H), 3.44 -3.32 (m, 4H), 3.30-3.20 (m, 4H), 2.75-2.63 (m, 1H), 2.59 (5, 4H), 2.55-2.43 (m, 3H), 2.37 (5, 3H), 2.29 (dd, J= 12.7, 6.7 Hz, 1H), 2.03-1.89 (m, 4H), 1.72 (d, J= 22.7 Hz, 8H), 1.46 (d, J= 7.2 Hz, 3H), 1.01 (dd, J = 11.5, 6.9 Hz, 6H). MS (ES) m/z (relative intensity) 784.25 (([M+ 2H]2)/2, 100).

1334177-86-4, As the paragraph descriping shows that 1334177-86-4 is playing an increasingly important role.

Reference£º
Patent; CANCER RESEARCH TECHNOLOGY LIMITED; VAN BERKEL, Patricius Henrikus Cornelis; HOWARD, Philip Wilson; WILLIAMS, David G; WO2015/159076; (2015); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1334177-86-4,1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid,as a common compound, the synthetic route is as follows.

EDCI .HCI (0.203 g, 1 .06 mmol, 1 .1 eq.) was added to a solution of compound 32 (0.86 g, 0.96 mmol, 1 .0 eq.) and Mal-dPEG8-OH (0.57 g, 0.96 mmol, 1 .1 eq.) in dry DCM (30 mL) and CHC (to give a clear solution). The clear solution was stirred at room temperature for 18h. then a further portion of EDCI.HCI (0.037 g, 0.19 mmol, 0.2 eq.) was added and reaction continued for a further 24h. The reaction mixture was diluted with DCM (70 mL) washed with water (100 mL), brine (100 mL), dried (MgS04) and evaporated under reduced pressure to give a yellow foam. Purification by flash column chromatography [CHC /MeOH 0% to 6% in 1 % increments] gave the product as an off white foam (0.56 g, 40%). Analytical Data: RT 6.13 min; MS (ES+) m/z (relative intensity) 1468 {[M + H]+ , 20), 1334177-86-4

1334177-86-4 1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid 51340955, apyrrolines compound, is more and more widely used in various fields.

Reference£º
Patent; MEDIMMUME LIMITED; HOWARD, Philip Wilson; DUNNY, Elizabeth; MASTERSON, Luke; (151 pag.)WO2017/137553; (2017); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

1334177-86-4, 1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid is a pyrrolines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

1-ethyl-3-(3?-dimethylaminopropyl)carbodiimide (EDCI, 33 mg, 0.172 mmol) was added to a solution of crude 63 (0.172 mmol) and Mal-(PEG)8-acid (100 mg, 0.172 mmol) in dry dichloromethane (10 mL). The reaction was stirred for 2 hours and the presence ofstarting material was no longer observed by LC/MS. The reaction was diluted withdichloromethane and washed sequentially with water and brine. The organic phase was dried over magnesium sulphate filtered and excess dichloromethane removed by rotary evaporation under reduced pressure. The resulting residue was subjected to flash column chromatography (silica gel; 100% chloroform to 10% methanol in chloroform). Pure fractions were collected and combined and excess eluent was removed by rotaryevaporation under reduced pressure to give 64 or DL5 (60 mg, 25% over 3 steps).

1334177-86-4, The synthetic route of 1334177-86-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; STEM CENTRX, INC.; SPIROGEN SARL; TORGOV, Michael; HOWARD, Philip Wilson; WO2014/130879; (2014); A2;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1334177-86-4,1-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-3-oxo-7,10,13,16,19,22,25,28-octaoxa-4-azahentriacontan-31-oic acid,as a common compound, the synthetic route is as follows.

[0496] The imine 32 (92 mg, 0.1 mmol, 1.1 equiv.) was dissolved in CHCI3 (6 mL) with one drop of anhydrous MeOH to aid dissolution. Maleimide-PEGs-acid (53 mg, 0.09 mmol, 1 equiv.) was added followed by EEDQ (33 mg, 0.14 mmol, 1.5 equiv.). This was left to stir vigorously at room temperature under Ar for 4 days until LC/MS analysis showed majority product formation. The solvent was removed in vacuo and the crude product was partially purified by silica gel column chromatography (CHC13 with 1% to 10% MeOH gradient) yielding 33 (81mg). The material was purified further by preparative HPLC to give 33 as a yellow solid (26.3 mg, 18%). Fast Formic run: LC/MS (1.39 min (ES+) m/z (relative intensity) 1485.00 ([M + H]+., 64)., 1334177-86-4

The synthetic route of 1334177-86-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; MEDIMMUNE LIMITED; LLOYD, Christopher O.; MARWOOD, Rose; HOWARD, Philip; HARPER, III, John W.; HOLLINGSWORTH, Robert; KAMAL, Adeela; DIMASI, Nazzareno; GAO, Changshou; TOADER, Dorin; WANG, Fengjiang; GINGIPALLI, Lakshmaiah; WO2015/155345; (2015); A1;,
Pyrroline – Wikipedia
1-Pyrroline | C4H7N – PubChem